Search results
Pulmonary Embolism Management
Start date:
Oct 07, 2025
Broadcast
Added:
11 months ago
TCT Conference 24 - PEERLESS II shows benefit of large-bore mechanical thrombectomy compared to catheter-directed thrombolysis for intermediate-risk pulmonary embolism (PE) patients.Dr Wissam A Jaber (Emory University Hospital Midtown, US) joins us onsite at TCT Conference to discuss the findings from PEERLESS (NCT06055920; Inari Medical).PEERLESS is a prospective, multicenter, randomized…
View more
Added:
1 year ago
EHRA 24 - Investigator, Dr William McIntyre (Population Health Research Institute, CA) joins us to discuss the findings from a substudy of ARTESiA (NCT01938248).ARTESiA was a randomized, parallel assignment clinical trial which aimed to assess if apixaban could reduce the risk of ischemic stroke and systemic embolism in patients with subclinical atrial fibrillation (AF) and additional risk…
View more
Added:
1 month ago
Filmed onsite at EASD 2025, this on-demand series features key insights from Prof Dirk Müller-Wieland and Dr Rahul Aggarwal to interpret the latest data on eicosapentaenoic acid(EPA), including the latest sub-analysis of the REDUCE-IT trial, whichanalysed the effectiveness of icosapent ethyl (IPE) on CV risk by triglyceride-glucose (TyG) index - an indicator of insulin resistance and risk of type…
View more
Added:
1 day ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Erin A Bohula (Brigham & Women's Hospital, US) to discuss the primary results of the VESALIUS-CV trial, a large-scale, phase 3, double-blind, randomised, placebo-controlled study sponsored by Amgen.The VESALIUS-CV trial (NCT03872401) evaluated the impact of evolocumab, a PCSK9…
View more
Added:
1 year ago
Watch this on-demand programme chaired by Prof Naveed Sattar (School of Cardiovascular and Metabolic Health, Glasgow, UK). Radcliffe Cardiology presents a distinguished panel of experts: Prof Gabriel Steg (University Institute of France, Paris, FR), Prof Lale Tokgozoglu (Hacettepe University, Ankara, TR), and Dr Joshua Stolker (St Louis Hospital, Missouri, US). This roundtable discussion explores…
View more
Added:
6 months ago
Added:
7 months ago
ACC 2025 - EVOLUT Low-Risk findings show the Medtronic TAVR system is a safe and effective treatment for aortic stenosis vs surgical valves at five years.Dr Michael Reardon (Houston Methodist, Texas, US) joins us onsite at ACC to discuss the EVOLUT Low Risk trial (NCT02701283; Medtronic Cardiovascular), investigating the safety and effectiveness of the Medtronic TAVR system compared to surgical…
View more
Added:
7 months ago
ACC 2025 - Individual-level data collected across 126 worldwide cohorts show controlling modifiable cardiovascular risk factors can potentially benefit life-years for freedom from CVD and death from any cause.Prof Christina Magnussen (University Heart and Vascular Centre Hamburg, Hamberg, DE) joins us onsite at ACC to discuss modifiable cardiovascular risk factors collected by the Global…
View more
Added:
6 months ago
ESC HF 25 - In a FINEARTS HF post-hoc analysis, the relative and absolute effects of finerenone relative to placebo did not significantly differ across kidney function.We are joined by Dr Safia Chatur (Mass General Cardiology, US) to discuss key findings from the FINEARTS-HF trial. This Phase 3 study evaluated the effect of finerenone versus placebo on cardiovascular death and total heart failure…
View more